New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:28 EDTONTYOncothyreon price target raised to $6 from $3 at Stifel
After speaking with a breast cancer physician consultant, Stifel thinks that Oncothyreon's ARRY-380 could be used to treat cancer that has spread from the breast to the central nervous system. The firm thinks that this indication could generate $47M of revenue for the company in 2022, and keeps a Buy rating on the stock.
News For ONTY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
10:03 EDTONTYHigh option volume stocks
High option volume stocks: HBB RENN ONTY LGF JMEI DK JO INTU TFM
May 15, 2015
10:13 EDTONTYHigh option volume stocks
High option volume stocks: POST SFM GSVC HGG HUN PH JWN CAR ONTY LBTYA
May 14, 2015
16:19 EDTONTYOn The Fly: Top stock stories for Thursday
Subscribe for More Information
10:09 EDTONTYIncreasing equity options volume on open
Increasing equity options volume on open: ONTY CBRL PBYI GWW AXLL IEV KSS EXPR UEC JACK
09:22 EDTONTYOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Perry Ellis (PERY), up 11.5%... Ctrip.com (CTRP), up 13.4%. ALSO HIGHER: AcelRx (ACRX), up 10.3% after being awarded contract worth up to $17M from Defense Dept to advance ARX-04... Oncothyreon (ONTY), up 16.9% after ASCO presentation data released... CYREN (CYRN), up 14.6% after announcing agreement with Dell.... Discovery Laboratories (DSCO), up 5.2% after Aerosurf shows positive Phase 2a data... Kate Spade (KATE), up 3.9% after being initiated with an Outperform at Wedbush. DOWN AFTER EARNINGS: Digital Ally (DGLY), down 16.4%... Kohl's (KSS), down 10.2%... VOXX (VOXX), down 8.1%... Cosi (COSI), down 7.3%. ALSO LOWER: Biotechnology (PBYI), down 15.1%% after Neratinib data published in ASCO abstract... Gevo (GEVO), down 10.7% after 4.3M share Spot Secondary priced at $4.00.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use